<DOC>
	<DOCNO>NCT01989754</DOCNO>
	<brief_summary>The purpose study assess effect canagliflozin compare placebo progression albuminuria participant Type 2 Diabetes Mellitus receive standard care inadequate glycemic control elevate risk cardiovascular event .</brief_summary>
	<brief_title>A Study Effects Canagliflozin ( JNJ-28431754 ) Renal Endpoints Adult Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The study conduct adult participant Type 2 Diabetes Mellitus ( T2DM ) , receive standard care hyperglycemia cardiovascular ( CV ) risk factor , either history prior CV event 2 risk factor CV event . Participants randomly assign 1:1 ratio canagliflozin match placebo take daily . Canagliflozin provide dose 100 mg/day Week 13 increase discretion investigator dose 300 mg/day , participant require additional glycemic control tolerate 100 mg dose . The study consist 2-week screening period double-blind treatment period last 78 156 week study completion April 2017 . A total 5,700 participant recruit study ; maximum duration study participant 3.5 year . Participants either drug na√Øve antihyperglycemic agent , use monotherapy , use combination antihyperglycemic therapy control blood glucose level .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Must diagnosis type 2 diabetes mellitus Must inadequate diabetes control ( define glycosylated hemoglobin level &gt; =7.0 % &lt; =10.5 % screen ) Greater equal ( &gt; = ) 30 yrs old history cardiovascular ( CV ) event , &gt; = 50 yr old high risk CV event Must either antihyperglycemic agent ( AHA ) therapy , AHA monotherapy , combination AHA therapy approve agent control blood glucose level . Exclusion Criteria History diabetic ketoacidosis , type 1 diabetes mellitus , pancreas betacell transplantation , diabetes secondary pancreatitis pancreatectomy History one severe hypoglycemic episode within 6 month screen History hereditary glucosegalactose malabsorption primary renal glucosuria Ongoing , inadequately control thyroid disorder Renal disease require treatment immunosuppressive therapy history chronic dialysis renal transplant Myocardial infarction , unstable angina , revascularization procedure , cerebrovascular accident within 3 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Albuminuria</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Cardiovascular outcome</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>T2DM</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Antihyperglycemic Agent</keyword>
</DOC>